AORT vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits a weak fundamental health with a Piotroski F-Score of just 2/9, indicating significant operational and financial concerns. Despite strong revenue growth of 18.4% and impressive recent earnings surprises, the negative profit margin (-2.16%) and negative ROE (-2.46%) reflect persistent profitability issues. Valuation metrics are stretched, with a Forward P/E of 50.97 and Price/Book of 4.65, while insider selling worth $9.73M signals management's lack of confidence. Although balance sheet liquidity is strong (Current Ratio: 3.93), the absence of Altman Z-Score and weak earnings quality undermine long-term sustainability.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AORT vs LLY: Head-to-Head Comparison
This page compares Artivion, Inc. (AORT) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.